Neurology · 2 h ago
Review proposes framework for dose control in therapeutic brain ultrasound
A review in BMC Medicine maps therapeutic brain ultrasound applications onto a shared acoustic parameter framework and proposes linking estimated exposure to biological effects and safety. The authors describe varied levels of clinical maturity, from established thermal ablation for selected indications to preclinical intracranial histotripsy and applications whose clinical efficacy remains uncertain.
- Review proposes linking acoustic exposure with biological effects and safety.
- Thermal ablation is established for selected indications.
- BBB opening’s incremental clinical benefit needs randomized evaluation.
- Intracranial histotripsy remains preclinical.
Therapeutic ultrasound is being investigated for brain interventions including thermal ablation, histotripsy, blood–brain barrier (BBB) opening, sonodynamic therapy and neuromodulation. This review organizes these approaches within a shared acoustic parameter space that includes frequency, pressure, pulse structure, skull transmission, biological mediators and tissue state; it is not a clinical trial and reports no pooled sample size or new patient outcomes.
The authors describe thermal ablation as clinically established for selected indications, with temperature-based monitoring. BBB opening has shown controllable permeability and enhanced drug delivery, but incremental clinical benefit still requires evaluation in randomized trials. Intracranial histotripsy remains preclinical. Sonodynamic therapy and neuromodulation have demonstrated feasibility or biological and physiological target engagement, while clinical efficacy has not been established consistently across indications.
The proposed dose-control framework separates patient-specific estimation of intracranial exposure, intraprocedural monitoring or dose surrogates, and post-treatment validation of intended effects and safety. Suggested readouts include magnetic resonance thermometry, cavitation emissions, sensitizer-linked pharmacodynamics and electrophysiological responses. The review emphasizes that exposure measures and biological effects are not interchangeable, and calls for modality-specific dose validation, controlled clinical evaluation and longitudinal safety assessment. The framework is a proposal, not evidence that it improves outcomes.
In practice
For clinicians considering brain ultrasound, the review distinguishes thermal ablation, described as established for selected indications, from BBB opening, sonodynamic therapy and neuromodulation, for which clinical benefit remains unestablished or inconsistent; intracranial histotripsy is still preclinical. It does not support changing practice. Its proposed framework links patient-specific exposure estimates, intraprocedural monitoring and post-treatment checks of biological effect and safety, but remains a conceptual proposal requiring controlled evaluation and longitudinal safety data.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
BMC Medicine: Therapeutic ultrasound for brain intervention: toward bioeffect-linked acoustic dose control ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.